<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091390</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0321</org_study_id>
    <secondary_id>CDR0000382120</secondary_id>
    <nct_id>NCT00091390</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer</brief_title>
  <official_title>Phase II Trial Of Combined High Dose Rate Brachytherapy And External Beam Radiotherapy For Adenocarcinoma Of The Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells.
      Internal radiation therapy uses radioactive material placed directly into or near a tumor to
      kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving internal radiation therapy together
      with external-beam radiation therapy works in treating patients with stage II or stage III
      prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the rate of late grade 3 or greater genitourinary and gastrointestinal
           toxicity after treatment with external beam radiotherapy and high-dose rate
           brachytherapy in patients with stage II or III adenocarcinoma of the prostate.

      Secondary

        -  Determine acute grade 3 or greater genitourinary and gastrointestinal toxicity in
           patients treated with this regimen.

        -  Determine freedom from biochemical failure in patients treated with this regimen.

        -  Determine overall survival of patients treated with this regimen.

        -  Determine disease-specific survival of patients treated with this regimen.

        -  Determine clinical relapse (local and/or distant) in patients treated with this regimen.

        -  Develop a quality assurance process for high-dose rate prostate brachytherapy.

      OUTLINE: This is a multicenter study. Patients are stratified according to prostate-specific
      antigen (≤ 10 ng/mL vs 11-20 ng/mL), T stage (T1c-T2c vs T3a-T3b), combined Gleason score
      (2-6 vs 7 vs 8-10), prior hormonal therapy (no vs yes), and timing of high-dose rate
      brachytherapy (before external beam radiotherapy vs after external beam radiotherapy).

      Patients undergo external beam radiotherapy over approximately 15 minutes once daily 5 days a
      week for 5 weeks. Patients also receive two fractions (within a 24-hour period) of high-dose
      rate brachytherapy (delivered through an implant inserted into the prostate) over
      approximately 5-30 minutes either before or after external beam radiotherapy. Treatment
      continues in the absence of disease progression or unacceptable toxicity.

      Patients are followed at 3, 7, 9, and 12 months, every 6 months for 5 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 110 patients will be accrued for this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Severe Genitourinary (GU) and Gastrointestinal (GI) Toxicity at 18 Months</measure>
    <time_frame>Beginning nine months after start of treatment.</time_frame>
    <description>Eighteen-month rate of late severe (grade 3-5) genitourinary (GU) and gastrointestinal (GI) toxicity, defined as starting more than 9 months from treatment start, and graded by CTCAE v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Severe GU and GI Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Within 9 Months of Starting Treatment</measure>
    <time_frame>From registration until 9 months from the start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Failure</measure>
    <time_frame>From registration to the date of biochemical failure or last follow-up. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From registration to the date of death or last follow-up. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific Survival</measure>
    <time_frame>From registration to the date of death due to prostate cancer or other disease related cause. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Progression Including Local/Regional and Distant Relapse</measure>
    <time_frame>From registration to the date of local/regional progression or distant relapse, or last follow-up. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>EBRT and HDR brachytherapy boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>External beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy boost.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR brachytherapy boost</intervention_name>
    <description>Brachytherapy could be performed before or after the external beam radiotherapy. The overall treatment course (external beam radiotherapy and brachytherapy) was limited to no longer than 8 weeks. 19 Gy in two fractions was to be given only to the clinical target volume (CTV). The first HDR treatment was to be delivered on the day of the catheter placement. The second treatment was to be delivered within 24 hours after the first treatment, but no less than 6 hours between implants.</description>
    <arm_group_label>EBRT and HDR brachytherapy boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>1.8 Gy given five times per week for a total dose of 45 Gy.</description>
    <arm_group_label>EBRT and HDR brachytherapy boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Clinical stage T1c-T3b

               -  No clinically or pathologically involved lymph nodes (N0 by pelvic CT scan or
                  MRI)

               -  No distant metastases (M0 by negative bone scan)

          -  Meets one of the following combination criteria:

               -  Clinical stage T1c-T2c, Gleason score 2-6, and prostate-specific antigen (PSA) &gt;
                  10 but ≤ 20 ng/mL

               -  Clinical stage T3a-T3b, Gleason score 2-6, and PSA ≤ 20 ng/mL

               -  Clinical stage T1c-T3b, Gleason score 7-10, and PSA ≤ 20 ng/mL

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Fertile patients must use effective contraception

          -  No hip prosthesis

          -  No major medical or psychiatric illness that would preclude study participation

          -  No prior invasive malignancy except nonmelanomatous skin cancer (e.g., carcinoma in
             situ of the oral cavity or bladder) or any other malignancy with a disease-free status
             ≥ 3 years

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for prostate cancer

        Endocrine therapy

          -  Prior induction hormonal therapy allowed provided therapy was initiated within 90 days
             before study enrollment

        Radiotherapy

          -  No prior pelvic or prostate radiotherapy

          -  No concurrent intensity-modulated radiotherapy

        Surgery

          -  No prior radical surgery for prostate cancer

          -  No prior transurethral resection of the prostate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Chow J. Hsu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center - Burbank</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Consultants Medical Associates at Daniel Freeman Memorial Hospital</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiological Associates of Sacramento Medical Group, Incorporated</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine and Blood Disorders - Scarborough</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital Regional Cancer Center</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8. doi: 10.1016/j.ijrobp.2009.08.048. Epub 2010 Mar 6.</citation>
    <PMID>20207506</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacob D, Raben A, Sarkar A, Grimm J, Simpson L. Anatomy-based inverse planning simulated annealing optimization in high-dose-rate prostate brachytherapy: significant dosimetric advantage over other optimization techniques. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):820-7. doi: 10.1016/j.ijrobp.2008.02.009. Epub 2008 May 1.</citation>
    <PMID>18455325</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <results_first_submitted>October 31, 2014</results_first_submitted>
  <results_first_submitted_qc>October 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2014</results_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EBRT and HDR Brachytherapy Boost</title>
          <description>External beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy boost.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125">Subjects contributing data to the primary analysis are considered to have completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible patients.</population>
      <group_list>
        <group group_id="B1">
          <title>EBRT and HDR Brachytherapy Boost</title>
          <description>External beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy boost.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="49" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Late Severe Genitourinary (GU) and Gastrointestinal (GI) Toxicity at 18 Months</title>
        <description>Eighteen-month rate of late severe (grade 3-5) genitourinary (GU) and gastrointestinal (GI) toxicity, defined as starting more than 9 months from treatment start, and graded by CTCAE v3.0</description>
        <time_frame>Beginning nine months after start of treatment.</time_frame>
        <population>All eligible patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBRT and HDR Brachytherapy Boost</title>
            <description>External beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy boost.</description>
          </group>
        </group_list>
        <measure>
          <title>Late Severe Genitourinary (GU) and Gastrointestinal (GI) Toxicity at 18 Months</title>
          <description>Eighteen-month rate of late severe (grade 3-5) genitourinary (GU) and gastrointestinal (GI) toxicity, defined as starting more than 9 months from treatment start, and graded by CTCAE v3.0</description>
          <population>All eligible patients.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" lower_limit="0.834" upper_limit="7.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The study is designed to test whether the 18-month late GU/GI toxicity following the protocol treatment is above 10% (hazard rate of 0.012/month). The sample size is determined so that the probability of rejecting the treatment because of excessive late toxicity is 90% if the true late toxicity rate is 20% (hazard rate of 0.025/month). Ninety-eight patients are required to with an additional 18 months of follow-up to have a statistical power of 90% with one-sided significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Z-test</method>
            <method_desc>One-sided.</method_desc>
            <param_type>hazard rate</param_type>
            <param_value>0.0014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Severe GU and GI Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Within 9 Months of Starting Treatment</title>
        <time_frame>From registration until 9 months from the start of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Failure</title>
        <time_frame>From registration to the date of biochemical failure or last follow-up. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From registration to the date of death or last follow-up. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-specific Survival</title>
        <time_frame>From registration to the date of death due to prostate cancer or other disease related cause. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Progression Including Local/Regional and Distant Relapse</title>
        <time_frame>From registration to the date of local/regional progression or distant relapse, or last follow-up. Analysis occurs after each patient has had 3 years of follow-up.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects with adverse event data. Subjects experiencing more than one of a given serious adverse event (SAE) are counted only once for that SAE. The same methodology was applied for non-SAE's.</desc>
      <group_list>
        <group group_id="E1">
          <title>EBRT and HDR Brachytherapy Boost</title>
          <description>External beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy boost.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fanconi syndrome acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Renal/genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urethral stricture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary bladder hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urogenital hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction NOS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hot flushes NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Proctitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Renal/genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urethral stricture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary bladder hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urogenital hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculatory disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction NOS</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flushes NOS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld</name_or_title>
      <organization>NRG Oncology</organization>
      <email>seiferheldw@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

